Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Stryker Corporation (SYK) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Stryker Corporation — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.8, while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Stryker Corporation is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPISYK
Sector
Income / Options OverlayTechnology
52-Week High
$49.54$394.34
52-Week Low
$37.98$282.58
Market Cap
$133.54B
Enterprise Value
$145.01B
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.88 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The ETF generates substantial income through weekly dividend distributions averaging $0.20-0.21 per share, funded by its covered call strategy on concentrated AI and tech holdings. Recent news highlights the fund's transition to weekly distributions and ongoing discussions about its aggressive income approach.

The high-yield strategy presents income opportunities but carries significant risk from NAV erosion during market downturns. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of 25% yields and concentrated exposure to volatile tech names warrant cautious positioning. The covered call approach limits upside potential while providing consistent cash flow.

Stryker Corporation

Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.

Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK